Effect of Soybean on Alzheimer
Phase 3
- Conditions
- Alzheimer's disease.Other degenerative diseases of the nervous systemG30-G32
- Registration Number
- IRCT20170702034861N9
- Lead Sponsor
- Kerman University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Age over 50 years old
Having a MMSE score between 16 and 24
Lack of substance abuse and alcohol abuse
Do not use anticoagulants
Lack of heart disease
Exclusion Criteria
depession
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Cognitive status of patients. Timepoint: 90-60-0day. Method of measurement: MMSD and CDR questionnair.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms of soybean extract (Glycine max L.) influence Alzheimer's disease progression in phase III trials?
How does standard hydroalcoholic soybean extract compare to cholinesterase inhibitors in Alzheimer's disease treatment outcomes?
Which biomarkers correlate with response to soybean seed extract in patients with Alzheimer's disease (G30-G32) in phase III studies?
What adverse events are associated with soybean hydroalcoholic extract in Alzheimer's disease trials and how are they managed?
Are there combination therapies involving soybean extract (Glycine max L.) and current Alzheimer's disease drugs that enhance efficacy?